Enveric Biosciences
ENVBEnveric Biosciences is a biotechnology company specializing in the development of next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders.
Earnings
Next report
Nov 12, 2026 (In 1 week)Competitors
Profile
Enveric Biosciences is a biotechnology company specializing in the development of next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company utilizes its proprietary discovery platform and a vast library of synthetic molecules to create non-hallucinogenic compounds designed to promote neuroplasticity. Its primary value proposition is providing fast-acting, durable treatments for depression and anxiety that can be administered in an outpatient setting.
Enveric is an early-stage drug developer focused on a niche within the psychedelic space, specifically targeting neuroplasticity without hallucinogenic side effects to enable broader clinical adoption.
FAQ
- What is Enveric Biosciences's market cap?
- Enveric Biosciences (ENVB) has a market capitalization of $6.5M and trades on NASDAQ.
- Who are Enveric Biosciences's competitors?
- Enveric Biosciences's key competitors include Alzamend Neuro, Inc. Common Stock, ABVC BioPharma, Inc. Common Stock, Tao Synergies Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Enveric Biosciences partner with?
- Enveric Biosciences's notable partners include MycoMedica Life Sciences, PBC, Aries Science & Technology, LLC, Restoration Biologics, LLC, and others.
- What subsidiaries does Enveric Biosciences have?
- Enveric Biosciences's subsidiaries include MagicMed Industries Inc., Akos Biosciences, Inc., Enveric Biosciences Canada, Inc..
- Where is Enveric Biosciences headquartered?
- Enveric Biosciences is headquartered in United States of America and employs approximately 26 people. It has been publicly traded since 1995.